Cirius Therapeutics
Cirius Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Cirius Therapeutics.
Cirius Therapeutics is a company.
Key people at Cirius Therapeutics.
Key people at Cirius Therapeutics.
Cirius Therapeutics is a clinical-stage biopharmaceutical company developing innovative small-molecule therapies targeting mitochondrial dysfunction to treat insulin resistance-driven diseases, including Type 2 Diabetes, obesity-related metabolic issues, and MASLD/MASH (formerly NASH).[1][2][4][5] Its lead candidate, azemiglitazone (MSDC-0602K), is an oral, once-daily second-generation insulin sensitizer that selectively modulates the mitochondrial pyruvate carrier (MPC) without activating PPAR-γ, avoiding safety issues of first-generation drugs like pioglitazone.[2][3] The company serves patients with chronic metabolic disorders, addressing overnutrition's cellular effects, and has shown promise in Phase 2 trials for MASH with fibrosis, with Phase 3 planning underway; it recently presented data on combinations with GLP-1 agonists like tirzepatide.[2][3][5]
Headquartered in San Diego, CA, and Kalamazoo, MI, Cirius has raised about $56.4M in funding, including a $40M Series A in 2017, supporting its pipeline momentum toward commercialization.[3][4]
Cirius Therapeutics was officially founded in 2016, building on research into thiazolidinediones (TZDs), first-generation insulin sensitizers for Type 2 Diabetes that showed NASH efficacy but had safety concerns like weight gain and heart risks.[3] The idea emerged from observations by researcher Ken Cusi, who demonstrated pioglitazone's benefits in NASH, prompting development of a safer MPC-targeted alternative.[3] CEO Bob Baltera leads the privately-held firm, with key scientific input from CSO Jerry Colca, who highlights the drug's design to exploit mitochondrial targets discovered in TZDs.[2]
Early traction came via a Series A round in April 2017, raising up to $40M led by Frazier Healthcare Partners and Novo A/S, joined by Adams Street Partners, Renaissance Venture Capital Fund, and Hopen Life Sciences Ventures.[3] This funded the EMMINENCE Phase 2b trial of MSDC-0602K in NASH patients with fibrosis, completed around 2019, paving the way for ongoing studies including 52-week trials in MASH with/without Type 2 Diabetes and recent combo data presentations.[2][3]
Cirius rides the wave of mitochondrial-targeted therapies in metabolic disease, capitalizing on surging demand for NASH/MASH and obesity treatments amid GLP-1 dominance (e.g., tirzepatide).[2][5] Timing aligns with regulatory shifts—like FDA's MASH breakthrough designations—and epidemiological pressures from rising insulin resistance, affecting millions with Type 2 Diabetes and liver fibrosis.[1][3][4] Market forces favor oral add-ons to injectables, where azemiglitazone's combo potential could enhance weight loss durability and fibrosis resolution without first-gen side effects.[2]
The company influences biotech by reviving TZD promise through precision targeting, contributing to a ecosystem shift toward cellular-level interventions in cardiometabolic epidemics, potentially enabling broader access via affordable orals.[2][3]
Cirius is primed for Phase 3 readouts and partnerships, with azemiglitazone eyeing approvals in MASH and Diabetes by late 2020s, boosted by GLP-1 combo data at ADA 2025.[2][5] Trends like mitochondrial drugging and oral-injectable synergies will propel it, amid $100B+ obesity markets. Its influence could grow via acquisitions or expansions into related indications, fulfilling insulin sensitizers' unmet potential in a post-GLP-1 era—transforming Cirius from clinical contender to metabolic therapy staple.[2][3]
